<DOC>
	<DOC>NCT00274690</DOC>
	<brief_summary>The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.</brief_summary>
	<brief_title>Post-Operative Nausea And Vomiting Study In Female Patients</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an Increased Emetogenic Risk</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Known, specified risk factors for PONV (post operative nausea and vomiting) Undergoing gynecologic or gallbladder surgery. pregnant or breastfeeding postmenopausal</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neurokinin-1 Receptor Antagonist</keyword>
	<keyword>GW679769</keyword>
	<keyword>Post-operative Nausea</keyword>
	<keyword>NK-1 Receptor Antagonist</keyword>
	<keyword>PONV</keyword>
	<keyword>Post-discharge Nausea and Vomiting</keyword>
	<keyword>PDNV</keyword>
	<keyword>Vomiting</keyword>
</DOC>